摩根大通证券公司:重申Savara评级

证券之星
19 Dec 2024

摩根大通证券公司:重申savara(SVRA.US)评级,由优于大市调整至优于大市评级,目标价由9.00美元调整至9.00美元。Savara(SVRA.US)公司简介:Savara Inc是一家生物制药公司。它专注于罕见的呼吸道疾病。该公司的主导项目molgramostim雾化溶液(molgramostim)是一种吸入性粒细胞-巨噬细胞集落刺激因子,处于自身免疫性肺泡蛋白沉积症(aPAP)的第3...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10